In discussing some current views on the biological characterization, radiotherapy and chemotherapy of brain tumours, I will concentrate on the commonly-occurring supratentorial gliomata of the astrocytic series. The malignant astrocytomata are highly invasive and often diffuse processes. The median survival of patients with these tumours is about 52 months; about 20% of patients are alive at the end of one year and less than 10% at the end of two years (Walker 1973) . Young patients fare better, and the age composition of a series is often significant. Variations in published survival data are mainly due to differing series' compositions and to the differing criteria for histological grouping, and it is regrettable that there is still no international, uniform and quantitative histological classification.
There are, of course, substantial difficulties which reflect the complexity both of the nervous system and of the tumour processes involved. The classical studies of Bailey and Cushing served to emphasize that the longest survivals were associated with the best-differentiated tumours, but what they also emphasizeda correlation with embryonic developmentcan now be seen as merely an expression of genetic derepression during oncogenesis. Their classification and descriptive approach influenced pathologists throughout the world so that some experienced workers have been reluctant to adopt a quantitative approach, arguing that it. engenders a spurious sense of accuracy. Kernohan & Sayre (1952) , who, introduced the grading system I-IV, found clear-cut differences in postoperative survival times, particularly for grades I and IV, although the 3-year survival rate did not differ between grades II and III. It should be noted that, in the United States, the term 'glioblastoma multiforme' may be synonymous with grades III and IV, while in this country its use is confined to grade IV; and a varying mixture of these grades can produce significantly different series results. Attempts at stratification, albeit within a continuum of histopathological appearances, are therefore to be encouraged, and the importance of recognizing grade III tumours from the point of view of radiotherapy will later be apparent at several points.
Biologically the important features, apart from anaplasia, are the widespread degenerative and vascular changes which are characteristic of glioblastoma. The areas of degeneration and necrosis may vary from microscopic foci to large cavities recognizable on needle biopsy. The vascular changes consist not only of thromboses, with multiple areas of tumour infarction and haemorrhage, but also the development of new vessels having small calibre, thin walls and endothelial proliferations; this vascular hyperplasia may be of such intensity as to resemble an angioma. Folkman and his colleagues in Boston (Brem et al. 1974 ) have applied his quantitative method of grading endothelial proliferationthe microscopic angiogenesis grading system (MAGS) -to astrocytomata, and for each consecutive grade the average MAGS score paralleled the malignancy of the tumour. Of the various histological features studied, the endothelial cytology (e.g. mitoses) correlated best with tumour cell anaplasia while capillary density correlated least.
Cell kinetics
The brain is unique in that neurons are incapable of cell division after birth, while glial cells of the supportive tissue retain their proliferative capacity with a low proliferation rate. Much of the work on brain cell kinetics in relation to tumours has been done by in San Francisco. While investigating cell kinetics of different human gliomas, they found that the labelling index (the percentage of mitoses labelled by radioactive thymidine, or the percentage of cells in S-phase) varied among gliomas and among different areas of the same tumour, and while it correlated reasonably well with histological characteristics, the relationship was not a strict one. Glioblastomas had an average labelling index of 5-10%, well differentiated astrocytomas 1% or less, and the anaplastic astrocytomas were somewhere in between. In contrast to this variability of labelling index in different types, the duration of Sphase (DNA synthesis) remained within 7-10 hours. Turnover timerelating duration of Sphase to labelling indexgives values for malignant gliomas of a few days to a week, and for astrocytomas it approaches two months. Calculations based solely on cell production would give doubling times of less than 5 days for glioblastoma: to accord with clinical observations of a possible doubling time of 5-6 weeks there must be a high cell loss factor which has been estimated at 80%, and this accords with the large areas of necrosis which are a feature of the more malignant tumours. What is important, of course, is the growth fraction (the ratio of the proliferating cells to the total of tumour cells), for this is an index of the proportion of the tumour cell population susceptible to 'cell cycle' or 'phase specific' drugs. Again the data come from Hoshino & Wilson who found growth fractions of 0.3 to 0.4 for glioblastoma multiforme, with cell cycle times of 2-3 days. As the labelling data came from intact areas of tumour, the growth fraction would be smaller for the whole tumour which contained necrotic areas, and if these occupied half the tumour the growth fraction might be as low as 15-20%. Cell cycle times for these tumours were about 57 hours ).
Radiotherapy
Clinically, the value of radiotherapy in individual cases and in selected series of malignant glioma has long been recognized, but it proved difficult to assemble series truly representative of the natural history of the tumours for comparative evaluation of surgery and postoperative irradiation. However, Sheline (1976 Sheline ( , 1977 combined data from various sources, classifying the tumours as either grade III or grade IV astrocytoma, and compared the results of 'resection only' and 'resection with postoperative irradiation'. Patients with grade III astrocytoma who were irradiated had greater 1-5 year survival rates than those unirradiatedthe average 5-year survival without irradiation being 2% compared with 16% for those having radiotherapy. For grade IV tumours the weighted averages of these data again showed a marked difference in favour of the irradiated groups. At one year the survival rates were 24% with irradiation and 8% without; at 3 years 6% of the irradiated were living but none of the unirradiated; but by 5 years there were no survivors in either group. From Sheline's review the importance of distinguishing between grades III and IV stands out clearly. Treatment of grade III lesions may, in about a fifth of cases, be actually curative, but while postoperative irradiation appears to increase survival for grade IV up to about 3 years, very few survive beyond this point.
As few malignant astrocytomas metastasize outside the cranium, the limiting factor in radiotherapeutic cure is the relative sensitivity of tumour and normal brain. The true and limited tolerance of brain, compared with connective tissue, has been determined mainly from collateral evidence when it has been incidentally irradiated. The changes consist particularly of areas of necrosis, haemorrhage, demyelination and gliosis, manifest clinically by progressive deficit occurring without evidence of raised pressure 3 months to 5 years after irradiation, but many small lesions may be silent. Pathologically, the changes may simulate the appearances of glioma and this, together with the brief survival and paucity of autopsies, makes cases of glioma unsuitable for assessment of the probability of necrosis in relation to levels of radiation dosage. The hypothalamus and brain stem are particularly vulnerable to dosage of over 5000 rad in 25 fractions in 5 weeks, while the tolerance of the cortical white matter is of the order of 5500 rad in 30 fractions in 6 weeks. Tissue tolerance to irradiation must, of course, be viewed in relation to the natural history of the disease being irradiated, and while the figures mentioned are useful when treating innocent tumours, such as those of the pituitary or glomus jugulare, very different considerations may apply in the management of rapidly fatal gliomata. There are, as yet, insufficient data for the normal brain from which to derive complete probability relationships for 5, 10, 20, or 50% injury levels as a function of the radiation factors of dose-time, fractionation pattern and volume. The greater the volume irradiated the lower the radiation tolerance, and because of lack of collateral circulation the central nervous system may be subject to different 'dose/volume' relationships from those for connective tissue. These considerations have to be kept in mind when assessing some recent trends in radiotherapy.
Anaplastic astrocytomas tend to spread widely within the brain, and despite the work of Scherer (1940) there is no doubt that they were, in the past, subjected to over-localized techniques of irradiation. Studies ranging from those of Kramer (Concannon et al. 1960 ) to those of Salazar & Rubin (1976) have shown that glioblastomas have been more extensive at autopsy than was expected on diagnostic assessment. Salazar & Rubin showed that only infrequently was glioblastoma confined to one lobe (35% of cases); usually it involved another adjacent lobe (45%) or the entire hemisphere (25%) and about 1 in 4 tumours crossed to the opposite hemisphere. In their series the diagnostic methods employed gave only 14% accuracy for determining tumour extent, and Salazar & Rubin therefore advocate whole-brain irradiation with boosting of a suitable target volume to higher dosage. Whole-brain irradiation is both simple and time-saving, but before it is universally adopted four points must be considered. First, diagnostic methods of tumour delineation are fast improving, and the pathological studies mentioned were done before the advent of EMI scanning. Secondly, and probably most important, in none of these studies was there evidence that the primary tumour had been sterilized, so that in practice the omission of small remote tumour foci has not been a deciding factor in the ultimate result. Thirdly, the brain stem is only at risk of invasion from temporal lobe tumours, and as this and the hypothalamus are particularly vulnerable to irradiation they should not be avoidably subjected to very high doses. Finally, there is the 'volume effect' already mentioned, and the rules formulated from connective tissue experience cannot be extrapolated to the nervous system.
With regard to radiation dosage, Salazar et al. (1976a) again analysed retrospectively the patterns of failure in the radiotherapy of 148 astrocytomas, and recognized that the most important factors influencing survival were tumour dosage and treatment volume. On the basis of this study they proposed that the whole brain should be treated to 5000-6000 rad and that the target volume be boosted to 7000-8000 rad. In a preliminary report (Salazar et al. 1976b) on such high-dose radiation therapy, in which 38 patients were compared with a previous 70 patients who had received 'standard dosage' of 5000-6000 rad, the high-dose group had a significant increase in survival. For the grade IV astrocytomas the median survival was 50 weeks compared with 34 weeks for the standard dose group; 56% were alive at one year compared with 29%. This difference in survival persisted for two years only; the cause of death in the high-dose group was in every case recurrence of tumour, and gross radiation necrosis was not seen although the microscopic vascular and neuronal changes were still being studied. The grade III cases were few in number and 4 out of 6 were still surviving.
The responsiveness of grade III cases has been seen in a number of previous series. In an early 1 MeV series (Jones 1960) , the median survival was 46 months, while in the series studied by Kramer (1973) , 5 out of 23 patients survived 5 years and almost three-quarters returned either to normal performance status or self-care. If the high-dosage method for irradiating malignant gliomata should become widely applied or be subjected to randomized trial of large numbers of patients, it will become even more important to recognize grade III tumours, for in those of grade IV high dosage merely increases the immediate survival, and if it proves to have undue late effects it may be advisable to reserve this treatment for the most malignant group only. All the patients in Salazar & Rubin's (1976) recent high-dose series had recurrence of tumour in fully irradiated volumes, with high doses of from 1590 ret or 6000 rad to 2000 ret or 8000 rad, and this emphasizes that tumour control is impossible by this means alone.
The widespread degenerative and vascular changes of glioblastoma, with necrosis and diminished blood flow, suggest that hypoxia may be an important factor in this radioresistance (for cells that are completely anoxic may survive about 3 times the radiation dose required to sterilize them if they were fully oxygenated). Attempts to overcome such an 'oxygen effect' in glioblastoma multiforme have been made by irradiation in hyperbaric oxygen; by using another type of radiation having high linear energy transfer (LET) and less dependence on the oxygen effect; and by using chemical radiosensitizers of hypoxic cells.
A controlled clinical trial with hyperbaric oxygen was undertaken by Chang et al. (1975) in New York with only minimal improvement in terms of survival, and this may be related to the intracranial vascular effects of hyberbaric oxygen itself. Fast neutrons, much less dependent than are photons on the oxygen effect, have been extensively investigated by the MRC team at Hammersmith Hospital, and a controlled comparison with photons (M Catterall & H J G Bloom, personal communication) has produced some most interesting results. For, while neutron dosage of 1560 rad/12 fractions/26 days was in fact able to sterilize glioblastomatous tumours, there was no improvement in survival because of a demyelinating syndrome in the normal brain reminiscent in some ways of that described by Rider (1963) for photons. Rather than it being a manifestation of the diminished oxygen effect, this may well be related to the different 'relative biological effectiveness' and the lesser capacity for repair of cellular sublethal damage from neutrons.
So we turn to chemical radiosensitization of hypoxic cells, and here there are indeed promising possibilities. The proposal in 1963 by Adams & Dewey that a relationship exists between the ability of a few chemical compounds to sensitize hypoxic bacterial cells and the electron-affinity of these compounds has led to the discovery of the radiosensitizing properties of the group of nitroimidazolesparticularly, in 1973, of metronidazole (Flagyl) and later, of the more effective Ro-07-0582 or misonidazole. A controlled trial of gamma radiation alone and radiation plus high dose metronidazole has been carried out in Edmonton, Alberta, by Urtasun et al. (1976) and the radiation regime should be noteda tumour dose of only 3000 rad in 9 fractions in 18 days (1288 rets) given by large parallel fields to two-thirds of the brain. The preliminary results indicated that patients receiving metronidazole 4 hours before brain irradiation had a significant delay in the time of tumour recurrence, presumably due to a higher degree of inactivation of the radioresistant hypoxic cell population. A recent report (Urtasun et al. 1977) , when nearly all these patients had died, confirms without change what was predicted when most of the patients were still alive, and the difference between the two groups is quite striking. The control group receiving only this relatively low radiation dosage produced survivals inferior to those of conventional X-ray therapy, but with metronidazole the results were as good as those of the American BTSG's study. Urtasun is now investigating higher radiation dosage with the newer agent, misonidazole, as are Professor N Bleehen and Dr C Wiltshire at Cambridge. A limiting factor in this promising approach is the incidence of sensory peripheral neuropathy from misonidazole and related to the total dose of drug used.
The trends, then, in radiotherapy have been towards whole-brain irradiation; to the use of higher dosage, often above the true tolerance of brain; and, most promisingly, to the use of hypoxic cell sensitizers.
Chemotherapy
Chemotherapy has been under investigation for over a decade and from the variety of drugs tested only the nitrosoureas have been shown to have significant activity. In relation to other situations in cancer chemotherapy, the malignant cell burden is small, by a factor of 1 or 2 log-fold compared with common intrathoracic or abdominal tumours. The factors influencing the outcome of chemotherapy have been analysed by Ausman (1973) and these range from the route of administration, the blood flow and drug distribution in the tumour and the microenvironment, to the tumour cell kinetics and sensitivity and the brain reaction to both tumour and drug.
Brain tumours do not have the same capillary barrier (BBB) which protects the brain from water-soluble drugs of more than 200 mol. wt, and Ausman & Levin (1969) have shown that water soluble molecules may enter experimental intracerebral tumours. Nevertheless, lipid solubility favours the entry of drugs into the central nervous system, and clinically the most effective drugs for treating intracerebral tumours have been the lipid-soluble ones, such as the nitrosoureas. Two special features of tumour spread and microcirculation may be important.
(1) The infiltrative cells usually appear in advance of the histologically apparent induced neovasculature and, while these cells have a higher growth fraction, they are, from the pharmacokinetic viewpoint, at a disadvantage since fewer drugs can penetrate (Levin 1975) . (2) In glioblastoma multiforme vascular shunts are present towards the centre of the tumour which may allow the drug to bypass some of the tumour cells (Ausman 1973) . While cell kinetic studies may help by indicating, for instance, that there is likely to be very limited benefit from cell-cycle-specific (CCS) drugs, the heterogeneity of cell population in malignant gliomas tends to nullify any detailed application, and more help in planning treatment is likely to come from pharmacokinetic studies.
The most successful of the clinically effective agents (Levin & Wilson 1975 ) are the nitrosoureas: BCNU, which is probably the most active, CCNU and methyl CCNUknown in USA as carmustine, lomustine, and semustine respectively. The toxicity of these is considerable, mainly haematological and cumulative. The leukopenia from a single dose is delayed to about 6 weeks and lasts 1-2 weeks, so that the spacing of doses must be at intervals of at least 6 weeks. Procarbazine, a methyl hydrazine compound, is oxidized to a lipophilic azo intermediate which crosses the blood brain barrier. BIC, an imidazole carboxamide, and epipodophyllotoxin (PTG) have also recently been shown to have clinical activity. The responses in these studies of single drugs, based on clinical improvement, varied between 25% and 50%, and they encouraged systematic evaluation in controlled trials, ultimately of multimodal therapy.
The best known of these trials was organized in the United States at the National Cancer Institutewith 8 participating neurosurgical services throughout the United States (the Brain Tumor Study Group) (Walker & Gehan 1972 , Walker 1975 ) -in order to determine the degree of efficacy of chemotherapy with and without radiotherapy. Patients in this four-arm study were randomized after surgery between BCNU (80 mg/m2/day intravenously every 6-8 weeks) with or without radiotherapy (whole brain 6000 rad/6 weeks) concurrently, or to the best conventional care. An interim report (Walker 1975) showed that the control group had a median survival of 17 weeks, while for those who received above 5000 rad radiotherapy it was 37 weeks, and for BCNU plus radiotherapy it was 40 weeks. This was the first investigation to show a significant increase in survival as the result of adjuvant chemotherapy; the side effects in the radiotherapy and adjuvant groups were identical, with platelet counts of about 95 000/mm3 on day 25. Clearly there will be many more such trials, such as those of the EORTC, and as these become more sophisticated, in order to assess various forms of multimodal therapy, we must remember the question of agent interactionsnot only of drug interaction (for example, Fewer et al. (1972) showed that the addition of vincristine was apparently detrimental), but also of drug and radiation interaction; for the schedules of radiotherapy used are likely to damage capillary endothelium, so affecting drug distribution, and the timing of chemotherapy may be critical.
Quality of survival
These studies have had survival as their principal target, but those caring for such patients know that it is only part, and possibly not the most important part, of the whole story. Maintained improvement in the clinical neurological state is what concerns the patient and his family, and objective response is exceedingly difficult to quantify. Goldsmith & Carter (1974) pointed out that so-called objective measurements of tumour size as determined by brain scan or angiogram are notoriously inaccurate, leaving evaluation of response to clinical assessment. The scheme presented by Rosenblum et al. (1973) , incorporating performance status, is a laudable attempt, but given the vagaries of cerebral oedema, especially where the use of steroids is uncontrolled, there must be scepticism of the critical evaluation of any objective response. Clinically glucocorticoids, e.g. dexamethasone, are the most dramatic agents in use today, and details of dosage and its actual administration in each individual case need to be incorporated in any trial protocol. Penman & Smith (1954) used the term 'useful survival' to mean that in their view 'a sensible onlooker, knowing and bearing in mind the sort of person the patient was before his illness, would on the whole be glad that he was still alive'. This is not readily assessable in terms of comparative statistics, and such subjective judgments will perplex clinicians for as long as the problems exist: often we wish we knew.
